Developer docs
API playgroundTry for free, no card

Search company profiles

Theragent

Full company profile

uuid000bfbm

Namestring
Theragent
Legal namestring
Theragent Inc.
Websiteurl
theragent.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Theragent is a full-service, cGMP-compliant contract development and manufacturing organization (CDMO) for cell and gene therapies, headquartered in Arcadia, California. Founded in 2019, the company operates two facilities — the Arcadia cGMP facility (11,250 sq. ft. of manufacturing space with four ISO 7/8 modular cleanroom suites, opened 2022) and the Covina Discovery Lab (6,000 sq. ft. for process and analytical development) — providing integrated services from preclinical research through commercial manufacturing for biotech and biopharma sponsors. Its manufacturing portfolio spans seven cell therapy modalities: CAR-T cells, regulatory T cells (Treg), induced pluripotent stem cells (iPSC), mesenchymal stem cells (MSC), hematopoietic stem cells (HSC), natural killer (NK) cells, and multicell combinations, supported by proprietary process assets including feeder-free NK cell expansion protocols, a suspension-adapted 293T lentiviral production line, and a CD137 tonic signaling assay.

Theragent's technical platform is differentiated by its Pharma 4.0 digital infrastructure, built on an exclusive multi-year partnership with Insight68 for AI-driven manufacturing software, delivering paperless electronic batch records, predictive production planning, and real-time client visibility through a secure web portal. Supporting services include process development, analytical development, quality assurance and control, regulatory affairs (including IND filing support), and digital supply chain management with barcoded sample tracking and cryopreservation monitoring. The company pursues a B2B enterprise sales motion targeting biotech and biopharma sponsors developing cancer immunotherapies and regenerative medicine products, generating revenue through project-based, multi-year contracts with quote-based pricing tied to manufacturing runs, analytical testing scope, and regulatory support requirements.

The company serves customers primarily through direct enterprise sales and industry conference engagement, with named clients including CellVax Therapeutics (manufacturing for the FDA-cleared IND-stage FK-PC101 prostate cancer immunotherapy) and Accelerated Biosciences (cGMP master cell bank production for human Trophoblast Stem Cells). Strategic technology partnerships include Pluristyx for end-to-end iPSC-derived therapy development and Insight68 for AI-driven manufacturing digitalization. Leadership comprises founder-CEO Yun Yen, MD/PhD (40+ years in oncology), CFO Joseph Huang, SVP Operations Weifeng Zhang (ex-Tanvex, GenScript, BMS), and VP Business Development Brian Newsom (ex-KBI Biopharma, Thermo Fisher), with headcount in the 11-50 range. No external funding rounds have been disclosed, indicating founder-financed growth.

Short descriptiontext

Theragent is a cGMP-compliant cell and gene therapy CDMO operating from Arcadia, California, providing end-to-end contract development, manufacturing, and regulatory services across seven cell therapy modalities for biotech and biopharma sponsors developing cancer and regenerative medicine products.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLos Angeles, United States
HQ citystring
Los Angeles
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cell therapy manufacturing, CDMO services, gene therapy production, GMP manufacturing, cell therapy development
Industry3 codes
PRIMARYHLAGABAD
Cell Therapy CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAAACAJ
Gene Therapy Vector Manufacturing & CDMO Services
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Biological Products, (No Disgnostic Substances)2836
Product category
Cell Therapy Contract Manufacturing (CDMO)
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1CDMO Manufacturing Services
TypeProfessional Services
Description

Contract Development and Manufacturing Organization providing end-to-end manufacturing and testing services for cell and gene therapy sponsors. Revenue is generated through project-based contracts for process development, analytical development, clinical manufacturing, and regulatory affairs support services

theragent.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Infrastructure, Technology or R&D, Operations, Supply Chain
Pricing details1 tier
1Custom project-based pricing
ModelOtherBilling cadenceMulti-year contract
Notes

Quote-based / Not publicly disclosed. Project pricing varies based on client requirements including number of manufacturing runs, analytical testing needs, and regulatory support scope.

theragent.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Theragent is a full-service, cGMP compliant cell and gene therapy Contract Development and Manufacturing Organization (CDMO) that provides end-to-end manufacturing, analytical testing, process development, and regulatory affairs services for biotech and biopharma sponsors. The company manufactures multiple cell therapy modalities (CAR-T, Treg, iPSC, MSC, HSC, NK cells, and multicell therapies) for cancer and rare disease applications at its 26,000 ft² facilities in Southern California.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Dramatically shorter batch turnaround times through in-house testing vs external laboratories
+2 more records
Product overview1 text field

Theragent is a full-service, cGMP compliant cell and gene therapy CDMO based in Southern California offering integrated contract development and manufacturing services. The company operates two facilities (Covina Discovery Lab for R&D and Arcadia cGMP Facility for clinical/commercial production) and manufactures seven distinct cell therapy modalities: CAR-T cells, Treg cells, iPSCs, MSCs, HSCs, NK cells, and multicell therapies. These manufacturing capabilities are supported by six core services spanning R&D, process development, analytical development, clinical manufacturing, quality assurance/control, regulatory affairs, and supply chain management. The company's Pharma 4.0-enabled infrastructure provides digital batch record compliance and real-time manufacturing transparency for clients developing cancer and rare disease treatments.

Product and service14 records
1CAR-T Cell Manufacturing
CategoryCell Therapy Manufacturing
Description

Genetically modified T-cell manufacturing services for chimeric antigen receptor (CAR) therapies, including patient collection, cell processing, and testing standards for clinical and commercial production.

2Treg Cell Manufacturing
CategoryCell Therapy Manufacturing
Description

Regulatory T cell (Treg) isolation, expansion, and banking services for immunosuppressive cellular therapies targeting autoimmune, inflammatory, and transplant-related diseases.

3iPSC Services
CategoryCell Therapy Manufacturing
Description

Induced pluripotent stem cell reprogramming, validation, banking, and differentiation services for regenerative medicine and allogeneic cell therapy development.

4MSC Manufacturing
CategoryCell Therapy Manufacturing
Description

Mesenchymal stem cell isolation, characterization, expansion, and differentiation services for tissue regeneration and immune modulation applications.

5HSC Manufacturing
CategoryCell Therapy Manufacturing
Description

Hematopoietic stem cell isolation, expansion, gene modification, and cryopreservation services for blood disease and immune disorder treatments.

6NK Cell Manufacturing
CategoryCell Therapy Manufacturing
Description

Natural killer cell activation and expansion services, including feeder-free platforms for solid tumor immunotherapy applications.

7Multicell Therapies
CategoryCell Therapy Manufacturing
Description

Co-culture manufacturing services for multiple cell type combinations, including NK/T-cell multicell conjugates for combined innate and adaptive immune response therapies.

8Research & Development
CategoryCDMO Service
Description

Preclinical research services including primary T cell culture, cell line generation, flow cytometry, and immunoassays for CAR-T and NK-based immunotherapy development.

9Process Development
CategoryCDMO Service
Description

Critical Quality Attribute and Critical Process Parameter establishment, scalability design, reagent optimization, and cell isolation/transduction services.

10Analytical Development
CategoryCDMO Service
Description

Method development for identity, purity, potency, and stability testing including flow cytometry, ELISA, cell-based assays, and qPCR/ddPCR.

11Clinical Manufacturing
CategoryCDMO Service
Description

cGMP clinical batch production for autologous and allogeneic cell therapies with in-house analytical testing and batch release services.

12Quality Assurance & Control
CategoryCDMO Service
Description

Endotoxin, mycoplasma, bioburden, sterility testing, environmental monitoring, and method validation services with electronic QMS integration.

13Regulatory Affairs
CategoryCDMO Service
Description

Strategic regulatory guidance, GAP assessments, IND filing support, and CMC life cycle management for cell and gene therapy programs.

14Supply Chain Management
CategoryCDMO Service
Description

Digital ERP-enabled supply chain with real-time patient sample tracking, demand forecasting, and cold chain management.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-05-07
Description

Partnership to provide seamless end-to-end pathway for iPSC-derived therapy development from iPSC derivation to commercial production. Pluristyx provides iPSC platform including licenses for iPSC derivation, consent for use, FailSafe functional suicide switch, and iACT Stealth Cells immune evasion technology. Programs are transferred to Theragent for GMP processing and clinical-to-commercial scale production.

Strategic tierCoreTypeTechnology or Integration
Description

Multi-year exclusive contract for AI-driven software to digitalize and streamline cell therapy manufacturing. Insight68 platform provides automated ordering, production planning, scheduling, and execution with real-time client access to batch runs. Includes electronic batch records, cGMP electronic equipment use logs, facility cleaning e-logbooks, and electronic lab notebooks.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Agreement for Theragent to produce cGMP-grade master cell bank (MCB) for Accelerated Biosciences' novel human Trophoblast Stem Cells (hTSCs). hTSCs are pluripotent and immune-privileged stem cells derived from an ethical source that can be differentiated into various cell therapies.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Manufacturing partnership for FK-PC101, CellVax's novel personalized cancer immunotherapy for prostate cancer. Theragent provides end-to-end manufacturing, release, and disposition of all clinical material from its Arcadia cGMP facility for Phase 2 clinical trials.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Single-cell analytics platform provider serving cell therapy developers with characterization tools. Adjacent to Theragent's analytical development services and competes for analytical method development budgets at CGT sponsors.

TypeBroad incumbent
Description

Global CDMO leader with a significant cell and gene therapy manufacturing footprint across multiple sites. Directly comparable to Theragent as a competitor for clinical and commercial CGT CDMO contracts, but operates at vastly larger scale and scope (biologics, small molecules, cell therapy).

TypeDirect peer
Description

Global CDMO with cell and gene therapy manufacturing capabilities and multiple GMP sites. Competes directly with Theragent for CGT clinical and commercial manufacturing contracts; larger scale but similar service-line breadth.

TypeDirect peer
Description

Biomanufacturing CDMO with significant cell and gene therapy capacity across multiple U.S. sites. Competes with Theragent for clinical and commercial CGT contracts; well-capitalized and pursuing a tech-enabled manufacturing strategy similar in spirit to Theragent's Pharma 4.0 approach.

TypeBroad incumbent
Description

Major CDMO with cell therapy manufacturing capabilities (recently acquired by Novo Holdings). Competes for the same CGT sponsor clients as Theragent and offers broader service lines including fill-finish and commercial-scale biologics manufacturing.

TypeEmerging player
Description

Emerging cell therapy manufacturing technology company developing automated, closed-system Cell Shuttle platforms for CGT CDMO services. Competes with Theragent for cell therapy manufacturing clients by offering automated, scalable alternatives to traditional cleanroom-based CDMOs.

TypeBroad incumbent
Description

CDMO arm of GenScript providing cell therapy, viral vector, and plasmid manufacturing services. Direct competitor in the CGT CDMO market; Theragent's SVP of Operations Weifeng Zhang previously served as VP and GMP Site Head at GenScript Probio USA.

TypeOthers
Description

iPSC platform provider partnered with Theragent (May 2024) to offer end-to-end iPSC-derived therapy development. While Pluristyx is a strategic partner rather than a competitor, it is ecosystem-relevant because its licensing model drives a pipeline of iPSC clients directly into Theragent's GMP operations.

9KBI Biopharma
TypeDirect peer
Description

Mid-sized CDMO offering cell therapy and biologics manufacturing services. Highly comparable to Theragent in scope and client profile; notably, Theragent's VP of Business Development Brian Newsom joined from KBI Biopharma, signaling close market positioning.

TypeBroad incumbent
Description

Large CRO/CDMO with cell and gene therapy manufacturing services via its Cell & Gene Therapy CDMO business. A direct competitor for CGT clinical manufacturing contracts, with broader discovery, safety, and CDMO capabilities than Theragent.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability1 record

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Theragent

Cell Therapy Contract Manufacturing (CDMO)theragent.com

Theragent is a cGMP-compliant cell and gene therapy CDMO operating from Arcadia, California, providing end-to-end contract development, manufacturing, and regulatory services across seven cell therapy modalities for biotech and biopharma sponsors developing cancer and regenerative medicine products.

What Theragent does

Theragent is a full-service, cGMP-compliant contract development and manufacturing organization (CDMO) for cell and gene therapies, headquartered in Arcadia, California. Founded in 2019, the company operates two facilities — the Arcadia cGMP facility (11,250 sq. ft. of manufacturing space with four ISO 7/8 modular cleanroom suites, opened 2022) and the Covina Discovery Lab (6,000 sq. ft. for process and analytical development) — providing integrated services from preclinical research through commercial manufacturing for biotech and biopharma sponsors. Its manufacturing portfolio spans seven cell therapy modalities: CAR-T cells, regulatory T cells (Treg), induced pluripotent stem cells (iPSC), mesenchymal stem cells (MSC), hematopoietic stem cells (HSC), natural killer (NK) cells, and multicell combinations, supported by proprietary process assets including feeder-free NK cell expansion protocols, a suspension-adapted 293T lentiviral production line, and a CD137 tonic signaling assay.

Theragent's technical platform is differentiated by its Pharma 4.0 digital infrastructure, built on an exclusive multi-year partnership with Insight68 for AI-driven manufacturing software, delivering paperless electronic batch records, predictive production planning, and real-time client visibility through a secure web portal. Supporting services include process development, analytical development, quality assurance and control, regulatory affairs (including IND filing support), and digital supply chain management with barcoded sample tracking and cryopreservation monitoring. The company pursues a B2B enterprise sales motion targeting biotech and biopharma sponsors developing cancer immunotherapies and regenerative medicine products, generating revenue through project-based, multi-year contracts with quote-based pricing tied to manufacturing runs, analytical testing scope, and regulatory support requirements.

The company serves customers primarily through direct enterprise sales and industry conference engagement, with named clients including CellVax Therapeutics (manufacturing for the FDA-cleared IND-stage FK-PC101 prostate cancer immunotherapy) and Accelerated Biosciences (cGMP master cell bank production for human Trophoblast Stem Cells). Strategic technology partnerships include Pluristyx for end-to-end iPSC-derived therapy development and Insight68 for AI-driven manufacturing digitalization. Leadership comprises founder-CEO Yun Yen, MD/PhD (40+ years in oncology), CFO Joseph Huang, SVP Operations Weifeng Zhang (ex-Tanvex, GenScript, BMS), and VP Business Development Brian Newsom (ex-KBI Biopharma, Thermo Fisher), with headcount in the 11-50 range. No external funding rounds have been disclosed, indicating founder-financed growth.

Theragent firmographics

Firmographics
Name
Theragent
Legal name
Theragent Inc.
Website
https://theragent.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
11–50 employees
Short description
Theragent is a cGMP-compliant cell and gene therapy CDMO operating from Arcadia, California, providing end-to-end contract development, manufacturing, and regulatory services across seven cell therapy modalities for biotech and biopharma sponsors developing cancer and regenerative medicine products.
Ownership category
akta.pro rank

Theragent industry classification

Industry
Product category
Cell Therapy Contract Manufacturing (CDMO)
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAGABAD
Cell Therapy CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAAACAJ
Gene Therapy Vector Manufacturing & CDMO Services
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Cell therapy manufacturing
  • CDMO services
  • Gene therapy production
  • GMP manufacturing
  • Cell therapy development

Where Theragent is headquartered

Location

Headquarters

HQ city
Los Angeles
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Theragent business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Infrastructure, Technology or R&D, Operations, Supply Chain

Revenue model

  1. CDMO Manufacturing Services: Contract Development and Manufacturing Organization providing end-to-end manufacturing and testing services for cell and gene therapy sponsors. Revenue is generated through project-based contracts for process development, analytical development, clinical manufacturing, and regulatory affairs support services

Pricing tiers

ModelBillingPrice
OtherMulti-year contractCustom project-based pricing

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Theragent product offering

Product offering

Core offering

Theragent is a full-service, cGMP compliant cell and gene therapy Contract Development and Manufacturing Organization (CDMO) that provides end-to-end manufacturing, analytical testing, process development, and regulatory affairs services for biotech and biopharma sponsors. The company manufactures multiple cell therapy modalities (CAR-T, Treg, iPSC, MSC, HSC, NK cells, and multicell therapies) for cancer and rare disease applications at its 26,000 ft² facilities in Southern California.

Product overview

Theragent is a full-service, cGMP compliant cell and gene therapy CDMO based in Southern California offering integrated contract development and manufacturing services. The company operates two facilities (Covina Discovery Lab for R&D and Arcadia cGMP Facility for clinical/commercial production) and manufactures seven distinct cell therapy modalities: CAR-T cells, Treg cells, iPSCs, MSCs, HSCs, NK cells, and multicell therapies. These manufacturing capabilities are supported by six core services spanning R&D, process development, analytical development, clinical manufacturing, quality assurance/control, regulatory affairs, and supply chain management. The company's Pharma 4.0-enabled infrastructure provides digital batch record compliance and real-time manufacturing transparency for clients developing cancer and rare disease treatments.

Differentiator

Problem solved

Functional benefit

Products and services

  • CAR-T Cell Manufacturing Genetically modified T-cell manufacturing services for chimeric antigen receptor (CAR) therapies, including patient collection, cell processing, and testing standards for clinical and commercial production.
  • Treg Cell Manufacturing Regulatory T cell (Treg) isolation, expansion, and banking services for immunosuppressive cellular therapies targeting autoimmune, inflammatory, and transplant-related diseases.
  • iPSC Services Induced pluripotent stem cell reprogramming, validation, banking, and differentiation services for regenerative medicine and allogeneic cell therapy development.
  • MSC Manufacturing Mesenchymal stem cell isolation, characterization, expansion, and differentiation services for tissue regeneration and immune modulation applications.
  • HSC Manufacturing Hematopoietic stem cell isolation, expansion, gene modification, and cryopreservation services for blood disease and immune disorder treatments.
  • NK Cell Manufacturing Natural killer cell activation and expansion services, including feeder-free platforms for solid tumor immunotherapy applications.
  • Multicell Therapies Co-culture manufacturing services for multiple cell type combinations, including NK/T-cell multicell conjugates for combined innate and adaptive immune response therapies.
  • Research & Development Preclinical research services including primary T cell culture, cell line generation, flow cytometry, and immunoassays for CAR-T and NK-based immunotherapy development.
  • Process Development Critical Quality Attribute and Critical Process Parameter establishment, scalability design, reagent optimization, and cell isolation/transduction services.
  • Analytical Development Method development for identity, purity, potency, and stability testing including flow cytometry, ELISA, cell-based assays, and qPCR/ddPCR.
  • Clinical Manufacturing cGMP clinical batch production for autologous and allogeneic cell therapies with in-house analytical testing and batch release services.
  • Quality Assurance & Control Endotoxin, mycoplasma, bioburden, sterility testing, environmental monitoring, and method validation services with electronic QMS integration.
  • Regulatory Affairs Strategic regulatory guidance, GAP assessments, IND filing support, and CMC life cycle management for cell and gene therapy programs.
  • Supply Chain Management Digital ERP-enabled supply chain with real-time patient sample tracking, demand forecasting, and cold chain management.

Quantifiable outcome

  • Dramatically shorter batch turnaround times through in-house testing vs external laboratories
  • +2 more outcomes

Companies that use Theragent

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles1 record

Theragent technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature6 records

Theragent partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core.

  • PluristyxcoreStrategic or Co-development Partner · 7 May 2024Partnership to provide seamless end-to-end pathway for iPSC-derived therapy development from iPSC derivation to commercial production. Pluristyx provides iPSC platform including licenses for iPSC derivation, consent for use, FailSafe functional suicide switch, and iACT Stealth Cells immune evasion technology. Programs are transferred to Theragent for GMP processing and clinical-to-commercial scale production.
  • Insight68coreTechnology or IntegrationMulti-year exclusive contract for AI-driven software to digitalize and streamline cell therapy manufacturing. Insight68 platform provides automated ordering, production planning, scheduling, and execution with real-time client access to batch runs. Includes electronic batch records, cGMP electronic equipment use logs, facility cleaning e-logbooks, and electronic lab notebooks.
  • Accelerated BiosciencescoreStrategic or Co-development PartnerAgreement for Theragent to produce cGMP-grade master cell bank (MCB) for Accelerated Biosciences' novel human Trophoblast Stem Cells (hTSCs). hTSCs are pluripotent and immune-privileged stem cells derived from an ethical source that can be differentiated into various cell therapies.
  • CellVax TherapeuticscoreStrategic or Co-development PartnerManufacturing partnership for FK-PC101, CellVax's novel personalized cancer immunotherapy for prostate cancer. Theragent provides end-to-end manufacturing, release, and disposition of all clinical material from its Arcadia cGMP facility for Phase 2 clinical trials.

Scale indicators7 records

Recent moves7 records

Expansion highlights5 records

Theragent competitors and assessment

Company assessment

Emerging players

  • IsoPlexis: Single-cell analytics platform provider serving cell therapy developers with characterization tools. Adjacent to Theragent's analytical development services and competes for analytical method development budgets at CGT sponsors.
  • Cellares: Emerging cell therapy manufacturing technology company developing automated, closed-system Cell Shuttle platforms for CGT CDMO services. Competes with Theragent for cell therapy manufacturing clients by offering automated, scalable alternatives to traditional cleanroom-based CDMOs.

Broad incumbents

  • Lonza: Global CDMO leader with a significant cell and gene therapy manufacturing footprint across multiple sites. Directly comparable to Theragent as a competitor for clinical and commercial CGT CDMO contracts, but operates at vastly larger scale and scope (biologics, small molecules, cell therapy).
  • Catalent: Major CDMO with cell therapy manufacturing capabilities (recently acquired by Novo Holdings). Competes for the same CGT sponsor clients as Theragent and offers broader service lines including fill-finish and commercial-scale biologics manufacturing.
  • GenScript Probio: CDMO arm of GenScript providing cell therapy, viral vector, and plasmid manufacturing services. Direct competitor in the CGT CDMO market; Theragent's SVP of Operations Weifeng Zhang previously served as VP and GMP Site Head at GenScript Probio USA.
  • Charles River Laboratories: Large CRO/CDMO with cell and gene therapy manufacturing services via its Cell & Gene Therapy CDMO business. A direct competitor for CGT clinical manufacturing contracts, with broader discovery, safety, and CDMO capabilities than Theragent.

Direct peers

  • AGC Biologics: Global CDMO with cell and gene therapy manufacturing capabilities and multiple GMP sites. Competes directly with Theragent for CGT clinical and commercial manufacturing contracts; larger scale but similar service-line breadth.
  • Resilience: Biomanufacturing CDMO with significant cell and gene therapy capacity across multiple U.S. sites. Competes with Theragent for clinical and commercial CGT contracts; well-capitalized and pursuing a tech-enabled manufacturing strategy similar in spirit to Theragent's Pharma 4.0 approach.
  • KBI Biopharma: Mid-sized CDMO offering cell therapy and biologics manufacturing services. Highly comparable to Theragent in scope and client profile; notably, Theragent's VP of Business Development Brian Newsom joined from KBI Biopharma, signaling close market positioning.

Others

  • Pluristyx: iPSC platform provider partnered with Theragent (May 2024) to offer end-to-end iPSC-derived therapy development. While Pluristyx is a strategic partner rather than a competitor, it is ecosystem-relevant because its licensing model drives a pipeline of iPSC clients directly into Theragent's GMP operations.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Theragent social profiles

Digital presence

Theragent compliance and trust

Trust signal

Compliance1 record

Theragent financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Theragent leadership team

Management profile

Number of profiles

Profiles5 records

Theragent funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Theragent M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Theragent

What does Theragent do?

Theragent is a full-service, cGMP compliant cell and gene therapy Contract Development and Manufacturing Organization (CDMO) that provides end-to-end manufacturing, analytical testing, process development, and regulatory affairs services for biotech and biopharma sponsors. The company manufactures multiple cell therapy modalities (CAR-T, Treg, iPSC, MSC, HSC, NK cells, and multicell therapies) for cancer and rare disease applications at its 26,000 ft² facilities in Southern California.

Is Theragent a public or private company?

Theragent is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Theragent founded?

Theragent was founded in 2019. It employs 11 to 50 people.

Where is Theragent based?

Theragent is headquartered in Los Angeles, United States, in the North America region.

How does Theragent make money?

One revenue line is on record: CDMO Manufacturing Services.

Who are Theragent's main competitors?

Emerging players on record are IsoPlexis and Cellares. Broad incumbents are Lonza, Catalent, GenScript Probio and Charles River Laboratories. Direct peers are AGC Biologics, Resilience and KBI Biopharma. Pluristyx is listed as an others.

Does Theragent have an API?

No public API is recorded for Theragent.

What industry is Theragent in?

Theragent's product category is Cell Therapy Contract Manufacturing (CDMO). Its primary akta.pro industry code is HLAGABAD, Cell Therapy CDMO, with a secondary code of HLAAACAJ, Gene Therapy Vector Manufacturing & CDMO Services. Its NAICS code is 325414 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireTheragent Expands Leadership Team with Weifeng "Frank" Zhang as Senior Vice President of OperationsTheragent Inc., a California-based CDMO focused on cell- and tissue-based therapies, has hired Weifeng "Frank" Zhang as Senior Vice President of Operations, effective March 2024. Zhang brings over 25 years of biotech industry experience, having previously served as Vice President of Manufacturing at Tanvex Biopharma and as Vice President and GMP Site Head at GenScript Probio USA. He will report directly to CEO Yun Yen and lead the company's operations team with the goal of optimizing GMP manufacturing processes using the company's Pharma 4.0 infrastructure.PR NewswireTheragent Welcomes Seasoned Cell Therapy Professional Brian Newsom as New Vice President of Business DevelopmentTheragent, a cell and gene therapy CDMO based in Arcadia, California, announced the appointment of Brian Newsom as Vice President of Business Development effective October 16, 2023. Newsom brings three decades of combined technical and business development experience in the cell therapy industry, having most recently served as Senior Director of Business Development at KBI Biopharma and previously held roles at Thermo Fisher Scientific, Life Technologies, and Invitrogen. CEO Yun Yen stated that Newsom's appointment aligns with Theragent's expansion phase as it seeks to grow its presence in the cell and gene therapy market.PR NewswireTheragent Embraces Pharma 4.0 with AI Software Provider, Insight68Theragent signed a multi-year exclusive contract with Insight68, an AI-driven software provider, to digitalize its cell therapy manufacturing. The partnership enables fully paperless batch records and real-time transparency, aiming to reduce inefficiencies and improve production scaling. Insight68's platform is compliant with FDA 21 CFR Part 11, GDPR, and HIPAA.PR NewswireTheragent Secures Novel Stem Cell Bank Production Contract with Accelerated BiosciencesTheragent, a cell therapy contract development and manufacturing organization (CDMO) based in Arcadia, California, has entered into an agreement with Accelerated Biosciences to produce a cGMP-grade master cell bank (MCB) for Accelerated Biosciences' novel human Trophoblast Stem Cells (hTSCs). The hTSCs are pluripotent, immune-privileged stem cells derived from an ethical source with patent protection, designed to serve as starting material for next-generation cell and gene therapies. The master cell bank, accompanied by a regulatory support package, will be available for purchase or licensing to industry partners in Q1 2023.PR NewswireCellVax Selects Theragent as Manufacturing Partner for Phase 2 Clinical Trial for Prostate Cancer ImmunotherapyTheragent, a cell therapy Contract Development and Manufacturing Organization based in Arcadia, California, has been selected by CellVax Therapeutics to provide manufacturing and testing services for FK-PC101, an autologous cancer vaccine candidate entering Phase 2 clinical trials for prostate cancer patients at high risk of recurrence after prostatectomy. Manufacturing services will commence in late 2022, with Theragent supplying autologous cell-derived doses from their cGMP manufacturing facility in Southern California. The partnership represents advancement of CellVax's proprietary tumor cell-based immunotherapy platform, which modifies patient tumor cells ex vivo to create personalized cancer vaccines.